廣告
香港股市 將在 39 分鐘 開市
  • 恒指

    19,636.22
    +82.61 (+0.42%)
     
  • 國指

    6,964.99
    +30.29 (+0.44%)
     
  • 上證綜指

    3,171.15
    +17.12 (+0.54%)
     
  • 道指

    39,806.77
    -196.82 (-0.49%)
     
  • 標普 500

    5,308.13
    +4.86 (+0.09%)
     
  • 納指

    16,794.88
    +108.91 (+0.65%)
     
  • Vix指數

    12.15
    +0.16 (+1.33%)
     
  • 富時100

    8,424.20
    +3.94 (+0.05%)
     
  • 紐約期油

    79.72
    -0.08 (-0.10%)
     
  • 金價

    2,429.80
    -8.70 (-0.36%)
     
  • 美元

    7.7975
    -0.0005 (-0.01%)
     
  • 人民幣

    0.9271
    0.0000 (0.00%)
     
  • 日圓

    0.0496
    -0.0001 (-0.12%)
     
  • 歐元

    8.4672
    +0.0013 (+0.02%)
     
  • Bitcoin

    71,329.38
    +5,030.78 (+7.59%)
     
  • CMC Crypto 200

    1,520.82
    +166.40 (+12.29%)
     

HRMY or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Harmony Biosciences Holdings, Inc. and Techne are sporting Zacks Ranks of #1 (Strong Buy) and #4 (Sell), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that HRMY is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

廣告

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

HRMY currently has a forward P/E ratio of 10.23, while TECH has a forward P/E of 35.87. We also note that HRMY has a PEG ratio of 0.43. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. TECH currently has a PEG ratio of 6.79.

Another notable valuation metric for HRMY is its P/B ratio of 3.41. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, TECH has a P/B of 5.09.

These metrics, and several others, help HRMY earn a Value grade of A, while TECH has been given a Value grade of D.

HRMY stands above TECH thanks to its solid earnings outlook, and based on these valuation figures, we also feel that HRMY is the superior value option right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report

Bio-Techne Corp (TECH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research